Combination therapy for relapsed follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, Mosunetuzumab and Tislelizumab, for people with relapsed or refractory follicular lymphoma. The goal is to see if this combination can help when at least two prior treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with follicular lymphoma that has come back or is not responding to treatment.
- You must have had at least two prior treatments, including one that targets the CD20 protein (like rituximab).
- You must be able to perform daily activities with little to no help (ECOG score 0 or 1).
- You must have measurable disease, meaning at least one tumor larger than 1.5 cm on a scan.
- Your liver, kidney, and blood counts must be within certain levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Mosunetuzumab for people with follicular lymphoma that has come back or stopped responding after at least two previous treatments. It is available through a compassionate use program for those who have no other options.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
This trial tests a combination of two targeted drugs, mosunetuzumab and zanubrutinib, for people with follicular lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
This Phase 2 study tests mosunetuzumab, an antibody treatment, for people with follicular lymphoma that relapsed (came back) or progressed soon after first treatment. It may help shrink the cancer again after early relapse or lack of response to standard therapy.
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
Hear when a new Relapsed/Refractory Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.